Levee Medical Announces that Patient Enrollment in the ARID II Pivotal Trial for the Voro® Urologic Scaffold has been Completed

On 14 July 2026, Levee Medical has finished patient enrollment in the ARID II trial for the Voro® Urologic Scaffold.  Moving forward with innovative urologic treatments and advancing regenerative devices toward commercialization to improve patient outcomes.

Levee Medical effectively enrolled patients in the ARID II trial for the Voro® Urologic Scaffold, a breakthrough trial that has evaluated sufficient participants for safety and efficacy assessment. This enhances healing, improves long-term results, and reduces post-prostatectomy complications, representing a transition towards biologically compatible devices. The trial now proceeds to follow-up and data collection before submitting findings to regulators. The Voro® Scaffold supports tissue healing in urologic procedures by ensuring structural support that encourages natural regeneration.

This milestone marks progress toward a device that could improve surgical outcomes and patient recovery. In ongoing research, if results are positive, Levee Medical may seek regulatory approval to market the Voro® Scaffold, expanding urologists' solution and advancing regenerative medicine. Reaching enrolment in ARID II is a major achievement, as recruiting suitable participants on schedule demonstrates strong engagement from healthcare providers and maintains the review.

Impact on the Medical Device Industry

The global medical devices market size is valued at USD 678.88 billion in 2025 and is projected to increase from USD 719.61 billion in 2026 to approximately USD 1,209.42 billion by 2035, expanding at a CAGR of 5.94% from 2026 to 2035.

According to Precedence Research, the industry's move toward regenerative technology is improving patient care and advancing medical device innovation. Completing patient enrollment in the ARID II trial marks a milestone for regenerative surgical tech, spotlighting ongoing innovation in medical devices. The Voro® Urologic Scaffold combines engineering with regenerative medicine to improve tissue reconstruction, surpassing traditional implants. Completion of enrollment indicates that the product has passed a key clinical stage, providing a vital mark for regulatory approval and potentially boosting investments in bioengineered scaffolds across various medical fields.

Manufacturers invest in products that enhance surgical structures and healing, integrating with advances in tissue engineering and biomaterials research. This milestone may boost investor confidence in companies developing advanced implantable devices, as demand for biocompatible surgical solutions grows amid healthcare providers seeking quicker recoveries and lower complications. The long-term success of this launch in medical devices depends on clinical outcomes and regulatory approval.

Impact on the Urology Industry

The global urology devices market size is calculated at USD 45.3 billion in 2025 and is predicted to increase from USD 47.57 billion in 2026 to approximately USD 73.16 billion by 2035, expanding at a CAGR of 4.91% from 2026 to 2035.

According to Precedence Research, ongoing innovation in urology and a commitment to developing better, patient-centered treatments through research. Completing enrollment in the ARID II trial is momentous for the urology industry, as it promotes research into high urologic reconstruction treatments. The Voro® Urologic Scaffold, which encourages natural tissue regeneration and aligns with technologies that enhance tissue healing, could improve surgical outcomes and long-term recovery. If effective, it could provide a new solution for tissue repair, postoperative issues, and better preserving urinary function.

In academic and community urology hubs, Voro® Urologic Scaffold success depends on follow-up, clinical evaluation, and regulatory approval. Hospitals benefit from greater efficiency in urology infrastructure, which reduces repeat procedures and follow-ups, potentially lowering costs and improving patient satisfaction. Reconstructive procedures often involve repairing urinary tissues, but current techniques can lead to complications involving scarring or reduced function.

Impact on the Regenerative Medicine Industry

The global regenerative medicine market size is estimated at USD 43.77 billion in 2025 and is projected to increase from USD 53.65 billion in 2026 to approximately USD 234.85 billion by 2035, expanding at a CAGR of 18.29% from 2026 to 2035.

According to Precedence Research, enrollment completion supports a shift toward biologically integrated healthcare that uses engineering and natural repair to improve outcomes across medical fields. The progress of the Voro® Urologic Scaffold's clinical trial highlights regenerative medicine's growing role in the biotechnology framework. Successful trials could lead to increased investment in orthopedic, wound-healing, and cardiovascular treatments to boost the body's healing ability and reduce complications.

Milestones ARID II trials boost investor confidence by reducing risks and demonstrating progress, but commercial success depends on effectiveness, approval, acceptance, and reimbursement. This underscores the need for collaboration among biomedical engineers, clinicians, surgeons, and regulators, as developing these solutions is multidisciplinary. Completing patient enrollment marks progress in turning research into clinical products, showing regenerative technology is nearing commercialization.

Expert Opinion

Completing patient enrollment in Levee Medical's ARID II trial represents a key innovation in the development of regenerative urologic devices and in the stage of collecting clinical data. This reflects effective trial management and keeps the company progressing toward regulatory submission. The Voro® Urologic Scaffold illustrates the move toward regenerative therapies that rely on the body's healing by replacing traditional implants.

From the expert's perspective, it could advance reconstructive urology by offering surgeons a new tissue-repair option. With continuous follow-up, analysis, and regulatory review, this is a positive sign of innovation. The trial's importance depends on clinical conclusions and evidence supporting the scaffold's future use. This milestone also benefits regenerative medicine, as successful trials provide vital clinical evidence for new biomaterials.